The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index; none of the 26 sources its claims cite is checked for support yet.
Healthcare resource utilization and costs associated with first versus subsequent use of cariprazine for bipolar I disorder
Open accessAbstract
Aims: To evaluate the healthcare resource utilization (HRU) and costs of patients who initiated cariprazine as their first versus subsequent atypical antipsychotic (AA) following a bipolar I disorder (BP-I) diagnosis. Methods: Adults with a BP-I diagnosis (first claim = index), commercial, Medicare Supplemental, or Medicaid insurance, and ≥1 outpatient cariprazine dispensing were identified from Merative MarketScan database. Cohorts included patients who initiated cariprazine as either their first or subsequent AA after initial BP-I diagnosis. Characteristics were balanced between cohorts using inverse probability of treatment weighting (IPTW). Outcomes evaluated post-index included all-cause and mental health (MH)–related HRU (hospitalizations, emergency department [ED] visits, outpatient visits), total healthcare costs (medical + pharmacy), and treatment patterns. HRU and healthcare costs were reported per patient-year (PPY) and compared between cohorts using rate ratios and 95% CIs estimated using nonparametric bootstrap procedures. Treatment patterns were analyzed descriptively, with standardized differences ≥10% considered important. Results: After IPTW, cohorts included 1,409 patients who initiated cariprazine first and 1,621 patients who initiated cariprazine subsequently; the average (standard deviation, SD) observation period was 678 (373) and 758 (389) days for first and subsequent initiators, respectively. Patients who initiated cariprazine first had 23% fewer all-cause hospitalizations and 28% fewer MH-related hospitalizations PPY (each comparison, p < 0.001). Rates of all-cause and MH-related outpatient visits were significantly lower in patients who initiated cariprazine first versus subsequently (each comparison, p < 0.001), while rates of ED visits were similar. Relative to subsequent initiators, first initiators incurred $2,587 and $2,130 lower all-cause and MH-related total healthcare costs PPY, respectively (each comparison, p < 0.05). Before starting cariprazine, first initiators used fewer BP-I–related medications on average than subsequent initiators (2.6 vs 3.9; standardized difference = 23.9%). Limitations: Potential coding inaccuracies and residual confounding. Conclusions: In this real-world database analysis, patients with BP-I who initiated cariprazine as their first AA had lower rates of HRU and incurred lower costs than patients who initiated cariprazine as a subsequent AA. © 2024 AbbVie. Published by Informa UK Limited, trading as Taylor & Francis Group.
Overview
CoChat Summary
TL;DR
In a retrospective US claims analysis, adults with bipolar I disorder (BP-I) who started cariprazine as their first atypical antipsychotic (AA) had lower healthcare resource utilization and costs than those who started cariprazine after another AA. The authors conclude that earlier cariprazine initiation may be associated with fewer hospitalizations and outpatient visits and lower total healthcare costs.
Key findings
- First initiators had 23% fewer all-cause hospitalizations and 28% fewer mental health (MH)-related hospitalizations per patient-year (PPY) than subsequent initiators (0.27 vs 0.35 PPY and 0.22 vs 0.31 PPY; each p < 0.001).
- First initiators had 12% fewer all-cause outpatient visits and 21% fewer MH-related outpatient visits (31.33 vs 35.58 PPY and 19.80 vs 25.09 PPY; each p < 0.001); ED visit rates were similar.
- Total all-cause healthcare costs were $2,587 lower PPY for first initiators ($18,318 vs $20,906; p < 0.05), and total MH-related healthcare costs were $2,130 lower PPY ($11,480 vs $13,611; p < 0.05).
- Before cariprazine, first initiators used fewer BP-I–related medications on average than subsequent initiators (2.6 vs 3.9; standardized difference = 23.9%).
Methods
- Retrospective claims-based analysis using Merative MarketScan Commercial, Medicare Supplemental, and Multi-State Medicaid databases; adults aged ≥18 years with a first BP-I diagnosis claim on or after January 1, 2016, and ≥1 outpatient cariprazine dispensing after index.
- Cohorts were patients who initiated cariprazine as their first AA after BP-I diagnosis (n = 1,409) versus those who initiated cariprazine after at least one other AA (n = 1,621); baseline characteristics were balanced using inverse probability of treatment weighting (IPTW).
- Outcomes included all-cause and MH-related hospitalizations, ED visits, outpatient visits, total healthcare costs (medical + pharmacy), and treatment patterns; HRU and costs were reported PPY and compared using rate ratios and 95% CIs from nonparametric bootstrap procedures.
Limitations
- Stated: potential coding inaccuracies and residual confounding; unmeasured confounding, including treatment resistance and unavailable socioeconomic variables; possible survivor bias; PPY comparisons cannot capture timing of HRU/costs; US-only data limit generalizability; part of the analysis occurred during the COVID-19 pandemic.
- Evident from the text: this is an observational claims analysis, so associations are not causal; cohorts differed in prior AA use and time from diagnosis to cariprazine initiation, and follow-up duration differed between groups.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 0 Not valid · 21 Not checked · 75 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Relative to patients who initiated cariprazine first, patients who initiated cariprazine subsequently used more BP-I–related medications (2.6 vs 4.0, std diff = 26.6%) and MH-related medications (3.8 vs 5.1, std diff = 19.0%) prior to cariprazine initiation.”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Despite $672 higher cariprazine costs PPY ($3,221 vs $2,550; p < 0.001), patients who initiated cariprazine first incurred $969 less PPY on all other branded AAs ($599 vs $1,567; p < 0.001) and $180 less PPY on generic AAs ($22 vs $202; p < 0.001) compared with patients who initiated cariprazine subsequently.”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“cariprazine costs were significantly higher for first versus subsequent initiators ($3,395 vs $2,785, p < 0.001), although costs for generic medications ($17 vs $238) and other branded AAs ($501 vs $1,193) were significantly lower (each comparison, p < 0.001).”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, there was no significant difference in all-cause or MH-related pharmacy costs between patients who first versus subsequently initiated cariprazine.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“patients who initiated cariprazine as their first AA had 12% fewer all-cause outpatient visits and 21% fewer MH-related outpatient visits than patients who initiated cariprazine as a subsequent AA (31.33 vs 35.58 PPY and 19.80 vs 25.09 PPY, respectively; each comparison, p < 0.001; ).”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
45 more claims
Create a free account to see all 96 claims and every source verdict.
- It may state two separate claims as one. 26
- Probably not a substantial claim. 27
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.-C., Saunders, L. D., Beck, C. A., Feasby, T. E., & Ghali, W. A. (2005) · Medical Care · doi:10.1097/01.mlr.0000182534.19832.83 · Cited by 10,669 · cited 1×
“Clinical characteristics were also evaluated during the baseline period, and included Quan-Charlson Comorbidity Index score 31 ; Elixhauser comorbidities 32 ; Diagnostic and Statistical Manual of Mental Disorders , 5 th Edition (DSM-5) 33 psychiatric comorbidities; conditions of particular interest…”
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852 · cited 1×
“Further, side effect profiles vary across individual AA agents 16 , and inadequate response and/or adverse effects can lead to patients cycling through multiple therapies or having subtherapeutic medication adherence 17,18 .”
Pacchiarotti, I., Bond, D. J., Baldessarini, R. J., Nolen, W. A., Grunze, H., Licht, R. W., Post, R. M., Berk, M., Goodwin, G. M., Sachs, G. S., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13020185 · Cited by 770 · cited 1×
“…date. g Cariprazine treatment duration was defined as the interval between the first cariprazine dispensing and the last cariprazine dispensing. the follow-up period, which could be reflective of comorbidities or the concerningly high use of antidepressant therapies for the treatment of BP-I 4,38 .”
Early Intervention in Bipolar Disorder
Vieta, E., Salagre, E., Grande, I., Carvalho, A. F., Fernandes, B. S., Berk, M., Birmaher, B., Tohen, M., & Suppes, T. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17090972 · Cited by 354 · cited 1×
“As delayed bipolar treatment is associated with negative outcomes such as longer hospital stays, increased relapse rates, increased risk of suicide, and worse psychosocial consequences 22–25 , it may be most beneficial to secure appropriate treatment early in the disease course.”
Correll, C. U. (2010) · European Psychiatry · doi:10.1016/s0924-9338(10)71701-6 · Cited by 273 · cited 1×
“Further, side effect profiles vary across individual AA agents 16 , and inadequate response and/or adverse effects can lead to patients cycling through multiple therapies or having subtherapeutic medication adherence 17,18 .”
Methods for Improving Regression Analysis for Skewed Continuous or Counted Responses
Afifi, A. A., Kotlerman, J. B., Ettner, S. L., & Cowan, M. (2007) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.28.082206.094100 · Cited by 263 · cited 1×
“HRU was reported per patient-year (PPY), with rates compared between weighted cohorts using rate ratios (RRs) obtained from Poisson regression models. p values and 95% confidence intervals (CIs) were estimated using nonparametric bootstrap procedures with 499 replications 34 .”
Fountoulakis, K. N., Grunze, H., Vieta, E., Young, A., Yatham, L., Blier, P., Kasper, S., & Moeller, H. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw109 · Cited by 248
Austin, P. C. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1673 · Cited by 238 · cited 1×
“Standardized differences (std diff) were used to analyze variations between cohorts; a std diff � 10% was considered a meaningful difference between cohorts 35 .”
Integrated Neurobiology of Bipolar Disorder
Maletic, V., & Raison, C. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00098 · Cited by 226 · cited 1×
“However, bipolar is a heterogeneous disorder, and different patients likely have different neurobiological underpinnings that may explain why some treatments are more effective than others 12–15 .”
Cited by
McIntyre, R. S., Parikh, M., Ta, J. T., Waraich, S., Cohen-Stavi, C. J., Marci, C. D., & Nabulsi, N. A. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2513766 · Cited by 6
Self-citationMasand, P. S., Clayton, A. H., Parikh, M., Haile, F., Germain, G., Ripley, S., Ma, S., Laliberté, F., & Nabulsi, N. A. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2587412 · Cited by 1
“Real-world research of patients with BP found that earlier cariprazine use is associated with better HRU outcomes 50 , and access barriers to cariprazine are associated with worse HRU outcomes 51 .”
Self-citationКОСТАДИНОВ, К., & Raycheva, R. (2026) · Research Square · doi:10.21203/rs.3.rs-10488927/v1
Metadata
- Authors
- Cutler, A. J., Laliberté, F., Germain, G., MacKnight, S. D., Boudreau, J., Wade, S. W., & Parikh, M.
- Affiliations
- SUNY Upstate Medical University (US)
- Groupe d’analyse
- Wade Outcomes Research and Consulting
- AbbVie (United States) (US)
- Corresponding author
- Parikh, Mousam
- ORCID
- Venue
- Journal of Medical Economics
- Publisher
- Informa UK Limited
- Published
- 2024-11-12
- Volume
- 27
- Issue
- 1
- Pages
- 1472-1484
- ISSN
- 1369-6998 (ISSN-L)
- 1941-837X
- OpenAlex
- W4404297940
- Cited by
- 3
- References
- 31
- Citations by year
- 2026: 1 · 2025: 2
- FWCI
- 0.71
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Journal of Medical Economics (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Figshare (cc-by)
- Funders
- AbbVie
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- cariprazine, bipolar I disorder, atypical antipsychotics, healthcare resource utilization, health care costs, hospitalization, emergency department visits, outpatient visits, polypharmacy, treatment patterns, real-world evidence, Medicare Supplemental, Medicaid, private insurance, inverse probability of treatment weighting, MarketScan
- MeSH terms
- Adolescent, Adult, Bipolar Disorder, Emergency Service, Hospital, Health Expenditures, Female, Health Resources, Health Services, Hospitalization, Humans, Insurance Claim Review, Male, Middle Aged, Patient Acceptance of Health Care, Piperazines, Retrospective Studies, Antipsychotic Agents, United States, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-26, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-26 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Healthcare resource utilization and costs associated with first versus subsequent use of cariprazine for bipolar I disorder. https://app.cochat.ai/papers/10.1080/13696998.2024.2419721
- The paper
- Cutler, A. J., Laliberté, F., Germain, G., MacKnight, S. D., Boudreau, J., Wade, S. W., & Parikh, M. (2024). Healthcare resource utilization and costs associated with first versus subsequent use of cariprazine for bipolar I disorder. Journal of Medical Economics. https://doi.org/10.1080/13696998.2024.2419721
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.